Characterization of HIV-1 genotypes and antiretroviral drug-resistanc mutations among patients in Burkina Faso

Pakistan Journal of Biological Sciences

Volumn 14, Issue 6, 2011, Pages 392-398

  Kagone, T S ^a   Hien, H ^a   Meda, N ^a   Diagbouga, P S ^a   Sawadogo, A ^b   Drabo, J ^b   Peeters, M ^c   Vergne, L ^c   Delaporte, E ^c   de Souza, C ^d   Gbeassor, M ^d   Simpore, J ^e  

^a CENTRE MURAZ   (Burkina Faso)

^b CHUSS Bobo Dioulasso ^*  (Burkina Faso)

^c Laboratoire de Retrovirologie IRD Montpellier   (France)

^d Faculte des Sciences Universite de Lome   (Togo)

^e UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

Author keywords

Burkina faso; Drug resistance; HAART; HIV 1 polymorphism; Mutations

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BURKINA FASO; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; STRUCTURAL GENE; VIROLOGY; VIRUS GENE;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; BURKINA FASO; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENES, POL; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; POLYMORPHISM, GENETIC; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1; JOTURUS PICHARDI;

EID: 79959659367     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2011.392.398     Document Type: Article

References (29)

1. Adje, C., R. Cheingsong, T.H. Roels, C. Maurice and G. Djomand, et al., 2001. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy inAbidjan, Cote d'Ivoire. J. Acquir. Immune. Defic. Syndr., 26: 501-506.
2. Agrawal, S., S. Sawant and J. Shastri, 2010. Prevalence of HIV-2 infection in Mumbai. Ind. J. Dermatol. Venereol. Leprol., 76: 709-710.
3. Almeida, F.J., E.N. Berezin, R. Rodrigues, M.A. Safadi, M.V. Arnoni, C. Oiveira and L.F. Brigido, 2009. Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1 -infected children. J. Pediatr. (Rio J.), 85: 104-109.
4. De Clercq, E., 2009a. Review anti-HIV drugs: 25 Compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 33: 307-320.
5. De Clercq, E., 2009b. The history of antiretrovirals: Key discoveries over the past 25 years. Rev. Med. Virol., 19: 287-299.
6. Delfraissy, J.F., 2002. Patients on Antiretroviral Treatment: Support for People Infected with HIV/AIDS, Recommended by Expert Groups. Flammarion, Paris, France, pp: 42-62.
7. Djoko, C.F., A.W. Rimoin, N. Vidal, U. Tamoufe and N.D. Wolfe et al., 2011. High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo. AIDS Res. Hum. Retroviruses, 27: 323-329.
8. Drabo, J., S. Minougou, M. Ouedraogo and M. Bambara, 2001. ARV treatment: Report of 45 patients followed in Ouagadougou. Proceedings of the 12th International Conference on AIDS and STDs in Africa. Dec. 9-13, Ouagadougou, Burkina Faso, pp: 233-233.
9. Eshleman, S.H., G. Becker-Pergola, M. Deseyve, L.A. Guay and M. Mracna, et al., 2001. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J. Infect. Dis., 184: 941-947.
10. Ilboudo, D., D. Karou, W.M.C. Nadembega, A. Savadogo and O.D.S. Pignatelli et al., 2007. Prevalence of human herpes virus-8 and hepatitis B virus among HIV seropositive pregnant women enrolled in the mother-to-child HIV transmission prevention program at saint Camille medical centre in Burkina Faso. Pak. J. Biol. Sci., 10: 2831-2837.
11. Ilboudo, D., J. Simpore, D.S. Sanou, D.J. Sia, D. Ouermi etal., 2009. Mother-to-child HIV andHHV- 8 transmission in neonates at saint camille medical centre in burkina faso. Pak. J. Biol. Sci., 12: 908-913.
12. Miedema, F., 2008. A brief history of HIV vaccine research: Stepping back to the drawing board?. AIDS., 22: 1699-1703.
13. Montavon, C., C. Toure-Kane, J.N. Nkengasong, L. Vergne and K. Hertogs et al., 2002. CRF06-cpx: A new circulating recombinant from of HIV-1 in west Africa involving subtypes A, G, K and J. J. Acquir. Immune. Defic. Syndr., 29: 522-530.
14. Nadembega, W.M., S. Giannella, J. Simpore, F. Ceccherini-Silberstein and V. Pietra et al., 2006. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J. Med. Virol., 78: 1385-1391.
15. Ouedraogo-Traore, R., C. Montavon, T. Sanou, N. Vidal and L. Sangare et al., 2003. CRF06-cpx is the predominant 1-HV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. AIDS, 17: 441-444.
16. Ouermi, D., J. Simpore, A.M.G. Belem, D.S. Sanou and D.S. Karou et al., 2009. Co-infection of Toxoplasma gondii with HBV in HIV-infected and uninfected pregnant women in Burkina Faso. Pak. J. Biol. Sci., 12: 1188-1193
17. Pignatelli, S., J. Simpore, V. Pietra, L. Ouedraogo and G. Conombo et al., 2006. Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop. Med. Int. Health, 11: 350-357.
18. Sagna, T., F. Djigma, M. Zeba, C. Bisseye, S.D. Karon and D. Ouermi, et al., 2010. Human papillomaviruses prevalence and genital co-infections in HIV-seropositive women in ouagadougou (burkma faso). Pak. J. Biol. Sci., 13: 951-955.
19. Simpore, J., V. Pietra, S. Pignatelli, D. Karou and W.M. Nadembega et al., 2007. Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso. J. Med. Virol., 79: 873-879.
20. Simpore, J., D. Ouenni, D. Ilboudo, A. Kabre and B. Zeba et al., 2009. Aetiology of acute gastro- enteritis in children at saint Camille Medical Centre, Ouagadougou, Burkina Faso. Pak. J. Biol. Sci., 12: 258-263.
21. Soares, R.O., P.R. Batista, M.G. Costa, L.E. Dardenne and P.G. Pascutti e at., 2010. Understanding the 1-HV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations. J. Mol. Graphics Modell., 29: 137-147.
22. Tebit, D.M., L. Sangare, A. Makamtse, S. Yameogo and H. Somlare, et al., 2008. HIV Drug Resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J. Acquir. Immune. Defic. Syndr., 49: 17-25.
23. Toni, T.D., P. Recordon-Pinson, A. Minga, D. Ekouevi and D. Bonard, et al., 2003. resence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res. Hum. Retroviruses, 19: 713-717.
24. Vahlne, A., 2009. A historical reflection on the discovery of human retroviruses. Retrovirology, 6: 40-40.
25. Varella, R.B., S.B. Ferreira, M.B. Castro, M.D. Tavares and M.G. Zalis, 2008. Prevalence of resistance-associated mutations in human immunodeficiency virus type 1-positive individuals failing HAART in Rio de Janeiro, Brazil. Braz. J. Infectious Dis., 12: 380-384.
26. Velazquez-Campoy, A., S. Vega, E. Fleming, U. Bacha, Y. Sayed, H.W. Dirr and E. Freire, 2003. Protease inhibition in African subtypes of HIV-1. AIDS Rev., 5: 165-171.
27. Vergne, L., M. Peeters, E. Mpoudi-Ngole, A. Bourgeois and F. Liegeois et al., 2000. Genetic diversity of protease and reverse transcriptase sequences in non- subtype-B human immunodeficiency virus type-1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J. Clin. Microbiol., 38: 3919-3925.
28. Wittkop, L., H.F. Gunthard, F. de Wolf, D. Dunn and A. Cozzi-Lepri et al., 2011. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect. Dis. 11: 363-371
29. Zhang, X.Q., 2010. The newest developments in anti-HIV- 1 drugs. Yao Xue Xue Bao., 45: 194-204